Developer docs
API playgroundTry for free, no card

Search company profiles

TheraPanacea

Full company profile

uuid0007rf3

Namestring
TheraPanacea
Legal namestring
TheraPanacea (Société Anonyme)
Websiteurl
therapanacea.eu
Company typeenum
Private
Founded yearint
2017
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
radiotherapy planning software, AI medical imaging, adaptive radiotherapy, oncology software, radiomics platform
Industry3 codes
PRIMARYHLAHABAJ
Radiology AI, CAD & Advanced Visualization Software
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACALAC
Vendor Neutral Archive (VNA) & Enterprise Imaging Repositories
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
NAICS code2 codes
  • Software Publishers5132
  • Irradiation Apparatus Manufacturing334517
SIC code2 codes
  • Services-Prepackaged Software7372
  • Surgical & Medical Instruments & Apparatus3841
Product category
Radiation Oncology AI Software
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1ART-Plan™ Software Licenses
TypeSubscription Recurring
Description

AI-powered radiotherapy software deployed to healthcare providers, generating recurring license revenue. Software is CE-marked and FDA/TGA cleared, deployed across 300+ centers in Europe and 230+ clinical instances worldwide.

therapanacea.eu
2Pharmaceutical AI/Biomarker Services
TypeLicensing Royalties
Description

ART-Omics platform offered to pharmaceutical companies for biomarker discovery, patient selection for clinical trials, and drug development optimization. Biogen collaboration provides up to $56M (including $15M convertible debt and $41M milestones).

therapanacea.eu
3Strategic Partnerships & Milestone Payments
TypeSubscription Recurring
Description

R&D collaboration agreements with pharma companies (Biogen) generating milestone-based payments contingent on achievement of research and development milestones.

therapanacea.eu
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Enterprise license for radiotherapy departments
ModelSubscriptionBilling cadenceAnnual
Notes

Quote-based pricing, not publicly disclosed

therapanacea.eu
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1ART-Plan™
Description

AI-powered radiotherapy software platform for adaptive cancer treatment planning, contouring, and treatment optimization. Includes modules for auto-contouring, image fusion, pseudo-CT generation, and adaptive radiotherapy decision support.

therapanacea.eu
+1 more record
Core offering1 text field

TheraPanacea develops and sells AI-powered medical device software for radiotherapy treatment planning and oncology. Its flagship ART-Plan™ platform automates contouring, image fusion, pseudo-CT generation, adaptive radiotherapy decision support, and treatment plan generation for cancer centers and radiotherapy departments. The company also offers ART-Omics™, an AI-driven radiomics platform for biomarker discovery used by pharmaceutical companies in drug development and clinical trial patient stratification.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • Up to 93% of time saved in contouring
+7 more records
Product overview1 text field

TheraPanacea offers a comprehensive AI-powered oncology platform centered on ART-Plan™/ART-Plan+™ for radiotherapy optimization. The core platform integrates multiple modules: Annotate (automated contouring), SmartFuse (image fusion), MR-Box (MR-only workflows), AdaptBox (adaptive radiotherapy decisions), SmartPlan (automated treatment planning), and TumorBox (brain tumor segmentation). The company also provides ART-Omics™ as a separate AI-powered biomarker discovery platform for pharmaceutical companies. The portfolio is complemented by Neuro Solutions for Alzheimer's Disease and Multiple Sclerosis applications. All products are designed for clinical use in radiation therapy settings, with CE-mark, FDA clearance, and TGA clearance for the main ART-Plan platform.

Product and service9 records
1ART-Plan™
CategoryAI-powered radiotherapy software platform
Description

AI-powered radiotherapy software platform that optimizes every step of the treatment process from preparation to follow-up for radiation oncologists, medical physicists, and dosimetrists at cancer centers and hospitals.

2ART-Plan+™
CategoryAI-powered radiotherapy software platform
Description

Enhanced ART-Plan medical device edition offering automatic treatment plan generation for supported prescriptions and anatomies, synthetic-CT generation, and improved processing precision for clinical radiotherapy teams.

3Annotate
CategoryAI radiotherapy contouring module
Description

Automated contouring solution providing zero-click, expert-level delineation of 250+ organs at risk and lymph nodes in up to 3 minutes for radiation oncology teams, delivering up to 95% time saving in contouring.

4SmartFuse
CategoryAI image fusion module
Description

AI-powered image fusion module providing high-precision rigid and elastic alignment between scans from different imaging modalities in a single click for radiotherapy planning workflows.

5MR-Box
CategoryMR-only radiotherapy workflow module
Description

MR-only workflow solution generating pseudo-CT from MR images for supported anatomies, including brain proton therapy, eliminating the need for a separate planning CT scan.

6AdaptBox
CategoryAdaptive radiotherapy decision support module
Description

AI-driven adaptive radiotherapy decision support module that generates synthetic CTs from Cone-Beam CTs, automates organ segmentation, and calculates dose distribution to determine when replanning is needed during a treatment course.

7SmartPlan
CategoryAI treatment planning module
Description

AI-powered automated treatment planning module that generates clinically acceptable radiotherapy treatment plans for prostate, breast, and head and neck workflows within the ART-Plan platform.

8TumorBox
CategoryAI brain tumor segmentation module
Description

AI-powered brain tumor auto-segmentation module delivering precision segmentation of brain tumors, including glioblastoma, with DSC scores up to 0.88 within the ART-Plan platform.

9ART-Omics™
CategoryAI radiomics and biomarker discovery platform
Description

AI-powered plug-n-play radiomics platform combining unsupervised biomarker discovery with clinical domain knowledge for advanced diagnosis, prognosis, and disease monitoring in neurosciences and oncology, marketed to pharmaceutical companies for biomarker discovery and clinical trial patient stratification.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2021-12-14
Description

Biogen and TheraPanacea collaboration in neuroscience to develop AI/ML solutions for personalized medicine. Biogen invests up to $15M in convertible debt plus up to $41M in milestone payments. Biogen gains exclusive rights to TheraPanacea technology in neuroscience. Collaboration aims to improve disease understanding and enable more personalized clinical trial design through medical imaging and AI analysis.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Leading French cancer center, one of the most prominent clinical collaborators for AI in radiation oncology research. Joint development of multiple studies and validation of AI tools.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Prestigious French cancer research and treatment center. Clinical collaboration partner for AI in radiation oncology research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Leading French comprehensive cancer center. Clinical collaborator with published testimonials on 60% time savings using Annotate and standardization benefits.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

French university hospital center participating in clinical research collaborations for AI in radiation oncology.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Leading US academic medical center. International collaboration partner for AI in radiation oncology research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic spin-off from CentraleSupélec, University of Paris-Saclay. Provides access to academic patents and research expertise. CEO Nikos Paragios is Distinguished Professor in Applied Mathematics at CentraleSupélec.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Swedish developer of RayStation treatment planning system and RayCare oncology information system, a direct competitor in AI-augmented radiotherapy planning and a validated integration partner for TheraPanacea's ART-Plan+ in plan generation.

TypeDirect peer
Description

US-based developer of AI-driven automation tools for radiation oncology workflows (auto-contouring, planning, QA), directly overlapping with TheraPanacea's ART-Plan modules targeting radiation oncology departments.

TypeDirect peer
Description

Finnish provider of AI-based auto-contouring solutions for radiotherapy, a focused direct competitor in the same AI contouring product category sold to European cancer centers.

TypeDirect peer
Description

Developer of AI auto-contouring software (Limbus Contour) for radiotherapy, competing head-to-head with TheraPanacea's Annotate module for OAR and lymph node delineation in clinical workflows.

TypeDirect peer
Description

UK-based medical imaging AI company specializing in oncology image analysis, deformable registration, and treatment planning automation — directly comparable to TheraPanacea's SmartFuse and broader imaging AI stack.

TypeDirect peer
Description

European AI radiology company (acquired by RadNet) focused on AI for lung nodule detection and oncology imaging, overlapping with TheraPanacea's clinical AI imaging capabilities for cancer care.

TypeBroad incumbent
Description

Global leader in radiation therapy equipment (LINACs) and oncology software (Mosaiq, Monaco), whose installed base shapes demand for TheraPanacea's contouring/planning software and competes broadly in AI-enabled radiotherapy.

TypeBroad incumbent
Description

Acquired by Siemens Healthineers, Varian is the dominant radiation oncology platform provider (Eclipse/ARIA) and a validated TPS integration partner for TheraPanacea, but also a competitor embedding AI in its own portfolio.

TypeEmerging player
Description

Australia-based AI company offering a broad radiology AI platform including chest X-ray and CT triage/detection models, adjacent to TheraPanacea's medical imaging AI capabilities for oncology workflows.

TypeBroad incumbent
Description

Diversified health technology incumbent offering imaging, treatment planning, and increasingly AI-driven oncology workflow tools, providing both competitive pressure and partnership context for AI radiotherapy vendors.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TheraPanacea

Radiation Oncology AI Softwaretherapanacea.eu

TheraPanacea firmographics

Firmographics
Name
TheraPanacea
Legal name
TheraPanacea (Société Anonyme)
Website
https://therapanacea.eu
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

TheraPanacea industry classification

Industry
Product category
Radiation Oncology AI Software
NAICS
Software Publishers (5132), Irradiation Apparatus Manufacturing (334517)
SIC
Services-Prepackaged Software (7372), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHABAJ
Radiology AI, CAD & Advanced Visualization Software
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACALAC
Vendor Neutral Archive (VNA) & Enterprise Imaging Repositories
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT

Keywords

  • Radiotherapy planning software
  • AI medical imaging
  • Adaptive radiotherapy
  • Oncology software
  • Radiomics platform

Where TheraPanacea is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices2 records

Markets served

TheraPanacea business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. ART-Plan™ Software Licenses: AI-powered radiotherapy software deployed to healthcare providers, generating recurring license revenue. Software is CE-marked and FDA/TGA cleared, deployed across 300+ centers in Europe and 230+ clinical instances worldwide.
  2. Pharmaceutical AI/Biomarker Services: ART-Omics platform offered to pharmaceutical companies for biomarker discovery, patient selection for clinical trials, and drug development optimization. Biogen collaboration provides up to $56M (including $15M convertible debt and $41M milestones).
  3. Strategic Partnerships & Milestone Payments: R&D collaboration agreements with pharma companies (Biogen) generating milestone-based payments contingent on achievement of research and development milestones.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise license for radiotherapy departments

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

TheraPanacea product offering

Product offering

Core offering

TheraPanacea develops and sells AI-powered medical device software for radiotherapy treatment planning and oncology. Its flagship ART-Plan™ platform automates contouring, image fusion, pseudo-CT generation, adaptive radiotherapy decision support, and treatment plan generation for cancer centers and radiotherapy departments. The company also offers ART-Omics™, an AI-driven radiomics platform for biomarker discovery used by pharmaceutical companies in drug development and clinical trial patient stratification.

Product overview

TheraPanacea offers a comprehensive AI-powered oncology platform centered on ART-Plan™/ART-Plan+™ for radiotherapy optimization. The core platform integrates multiple modules: Annotate (automated contouring), SmartFuse (image fusion), MR-Box (MR-only workflows), AdaptBox (adaptive radiotherapy decisions), SmartPlan (automated treatment planning), and TumorBox (brain tumor segmentation). The company also provides ART-Omics™ as a separate AI-powered biomarker discovery platform for pharmaceutical companies. The portfolio is complemented by Neuro Solutions for Alzheimer's Disease and Multiple Sclerosis applications. All products are designed for clinical use in radiation therapy settings, with CE-mark, FDA clearance, and TGA clearance for the main ART-Plan platform.

Differentiator

Problem solved

Functional benefit

Brands

  • ART-Plan™: AI-powered radiotherapy software platform for adaptive cancer treatment planning, contouring, and treatment optimization. Includes modules for auto-contouring, image fusion, pseudo-CT generation, and adaptive radiotherapy decision support.
  • ART-Omics™

Products and services

  • ART-Plan™ AI-powered radiotherapy software platform that optimizes every step of the treatment process from preparation to follow-up for radiation oncologists, medical physicists, and dosimetrists at cancer centers and hospitals.
  • ART-Plan+™ Enhanced ART-Plan medical device edition offering automatic treatment plan generation for supported prescriptions and anatomies, synthetic-CT generation, and improved processing precision for clinical radiotherapy teams.
  • Annotate Automated contouring solution providing zero-click, expert-level delineation of 250+ organs at risk and lymph nodes in up to 3 minutes for radiation oncology teams, delivering up to 95% time saving in contouring.
  • SmartFuse AI-powered image fusion module providing high-precision rigid and elastic alignment between scans from different imaging modalities in a single click for radiotherapy planning workflows.
  • MR-Box MR-only workflow solution generating pseudo-CT from MR images for supported anatomies, including brain proton therapy, eliminating the need for a separate planning CT scan.
  • AdaptBox AI-driven adaptive radiotherapy decision support module that generates synthetic CTs from Cone-Beam CTs, automates organ segmentation, and calculates dose distribution to determine when replanning is needed during a treatment course.
  • SmartPlan AI-powered automated treatment planning module that generates clinically acceptable radiotherapy treatment plans for prostate, breast, and head and neck workflows within the ART-Plan platform.
  • TumorBox AI-powered brain tumor auto-segmentation module delivering precision segmentation of brain tumors, including glioblastoma, with DSC scores up to 0.88 within the ART-Plan platform.
  • ART-Omics™ AI-powered plug-n-play radiomics platform combining unsupervised biomarker discovery with clinical domain knowledge for advanced diagnosis, prognosis, and disease monitoring in neurosciences and oncology, marketed to pharmaceutical companies for biomarker discovery and clinical trial patient stratification.

Quantifiable outcome

  • Up to 93% of time saved in contouring
  • +7 more outcomes

Companies that use TheraPanacea

Customer profile

Named customers5 records

Segments2 records

Ideal customer profiles2 records

TheraPanacea technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability7 records

Feature8 records

TheraPanacea partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered flagship and core.

  • BiogenflagshipStrategic or Co-development Partner · 14 December 2021Biogen and TheraPanacea collaboration in neuroscience to develop AI/ML solutions for personalized medicine. Biogen invests up to $15M in convertible debt plus up to $41M in milestone payments. Biogen gains exclusive rights to TheraPanacea technology in neuroscience. Collaboration aims to improve disease understanding and enable more personalized clinical trial design through medical imaging and AI analysis.
  • Gustave RoussycoreStrategic or Co-development PartnerLeading French cancer center, one of the most prominent clinical collaborators for AI in radiation oncology research. Joint development of multiple studies and validation of AI tools.
  • Institut CuriecoreStrategic or Co-development PartnerPrestigious French cancer research and treatment center. Clinical collaboration partner for AI in radiation oncology research.
  • Centre Léon BérardcoreStrategic or Co-development PartnerLeading French comprehensive cancer center. Clinical collaborator with published testimonials on 60% time savings using Annotate and standardization benefits.
  • CHU NîmescoreStrategic or Co-development PartnerFrench university hospital center participating in clinical research collaborations for AI in radiation oncology.
  • Penn MedicinecoreStrategic or Co-development PartnerLeading US academic medical center. International collaboration partner for AI in radiation oncology research.
  • CentraleSupélec / University of Paris-SaclaycoreStrategic or Co-development PartnerAcademic spin-off from CentraleSupélec, University of Paris-Saclay. Provides access to academic patents and research expertise. CEO Nikos Paragios is Distinguished Professor in Applied Mathematics at CentraleSupélec.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

TheraPanacea competitors and assessment

Company assessment

Direct peers

  • RaySearch Laboratories: Swedish developer of RayStation treatment planning system and RayCare oncology information system, a direct competitor in AI-augmented radiotherapy planning and a validated integration partner for TheraPanacea's ART-Plan+ in plan generation.
  • Radformation: US-based developer of AI-driven automation tools for radiation oncology workflows (auto-contouring, planning, QA), directly overlapping with TheraPanacea's ART-Plan modules targeting radiation oncology departments.
  • MVision AI: Finnish provider of AI-based auto-contouring solutions for radiotherapy, a focused direct competitor in the same AI contouring product category sold to European cancer centers.
  • Limbus AI: Developer of AI auto-contouring software (Limbus Contour) for radiotherapy, competing head-to-head with TheraPanacea's Annotate module for OAR and lymph node delineation in clinical workflows.
  • Mirada Medical: UK-based medical imaging AI company specializing in oncology image analysis, deformable registration, and treatment planning automation — directly comparable to TheraPanacea's SmartFuse and broader imaging AI stack.
  • Aidence: European AI radiology company (acquired by RadNet) focused on AI for lung nodule detection and oncology imaging, overlapping with TheraPanacea's clinical AI imaging capabilities for cancer care.

Broad incumbents

  • Elekta: Global leader in radiation therapy equipment (LINACs) and oncology software (Mosaiq, Monaco), whose installed base shapes demand for TheraPanacea's contouring/planning software and competes broadly in AI-enabled radiotherapy.
  • Varian Medical Systems (Siemens Healthineers): Acquired by Siemens Healthineers, Varian is the dominant radiation oncology platform provider (Eclipse/ARIA) and a validated TPS integration partner for TheraPanacea, but also a competitor embedding AI in its own portfolio.
  • Philips HealthSuite / Philips Radiation Oncology: Diversified health technology incumbent offering imaging, treatment planning, and increasingly AI-driven oncology workflow tools, providing both competitive pressure and partnership context for AI radiotherapy vendors.

Emerging players

  • Annalise.ai: Australia-based AI company offering a broad radiology AI platform including chest X-ray and CT triage/detection models, adjacent to TheraPanacea's medical imaging AI capabilities for oncology workflows.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

TheraPanacea social profiles

Digital presence

TheraPanacea compliance and trust

Trust signal

Compliance4 records

TheraPanacea financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TheraPanacea leadership team

Management profile

Number of profiles

Profiles3 records

TheraPanacea funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TheraPanacea M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TheraPanacea

What does TheraPanacea do?

TheraPanacea develops and sells AI-powered medical device software for radiotherapy treatment planning and oncology. Its flagship ART-Plan™ platform automates contouring, image fusion, pseudo-CT generation, adaptive radiotherapy decision support, and treatment plan generation for cancer centers and radiotherapy departments. The company also offers ART-Omics™, an AI-driven radiomics platform for biomarker discovery used by pharmaceutical companies in drug development and clinical trial patient stratification.

Is TheraPanacea a public or private company?

TheraPanacea is a private company. It is classified as venture growth investor backed and is currently operating.

When was TheraPanacea founded?

TheraPanacea was founded in 2017. It employs 51 to 100 people.

Where is TheraPanacea based?

TheraPanacea is headquartered in Paris, France, in the Europe region.

How does TheraPanacea make money?

Three revenue lines are on record. ART-Plan™ Software Licenses are the primary driver. The others are pharmaceutical AI/Biomarker Services and strategic Partnerships & Milestone Payments.

Who are TheraPanacea's main competitors?

Direct peers on record are RaySearch Laboratories, Radformation, MVision AI, Limbus AI, Mirada Medical and Aidence. Broad incumbents are Elekta, Varian Medical Systems (Siemens Healthineers) and Philips HealthSuite / Philips Radiation Oncology. Annalise.ai is listed as an emerging player.

Does TheraPanacea have an API?

No public API is recorded for TheraPanacea.

What industry is TheraPanacea in?

TheraPanacea's product category is Radiation Oncology AI Software. Its primary akta.pro industry code is HLAHABAJ, Radiology AI, CAD & Advanced Visualization Software, with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 5132 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Longevity.TechnologyNew AI research reshapes neuroprotective drug discovery fundingBCC Research published a Pulse report titled "AI Impact on Neuroprotective Agents" forecasting the North American neuroprotective agents market to grow at approximately 4.5% CAGR through 2030, with hundreds of millions flowing into AI-driven neuroscience startups. The research documents intensifying pharma-tech collaborations including Eli Lilly's partnership with NVIDIA to build an AI supercomputer, a $200 million joint venture between MeiraGTx and Hologen, and Biogen's work with TheraPanacea, while identifying recent venture raises by Nilo Therapeutics, Verge Genomics, Chai Discovery, NRG Therapeutics, BEXORG, and Illimis Therapeutics. The report frames these developments as creating new investor opportunities and describes AI deployment across the drug discovery value chain from target identification to precision dosing.EsmoEmbracing interdisciplinary collaboration for an AI-driven oncologyESMO, the European Society for Medical Oncology, has expanded its membership to include professionals from diverse fields such as data science and mathematics to support AI-driven cancer care. Nikos Paragios, founder and CEO of AI medical technology company TheraPanacea, explains in an interview how AI and machine learning can standardize radiotherapy and replicate best treatment practices across hospitals globally. Paragios emphasizes managing expectations in the field, noting that the biggest impact often comes from solving practical problems clinicians face rather than pursuing advanced breakthroughs.GlobeNewswireBiogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in NeuroscienceBiogen and TheraPanacea announced a collaboration to develop AI and machine learning digital health solutions for neuroscience. Biogen will invest up to $15 million for convertible debt and receive up to $41 million in milestone payments, gaining exclusive rights to TheraPanacea's technology in neuroscience.